PubRank

P P Hung

Author PubWeight™ 58.53‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Isolation and characterization of proteins from Rous sarcoma virus. Virology 1971 2.66
2 Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV. Vaccine 1992 1.79
3 Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 1994 1.63
4 Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 1997 1.62
5 Rolling circular DNA associated with Dane particles in hepatitis B virus. Nature 1975 1.50
6 Expression of hepatitis B surface antigen with a recombinant adenovirus. Proc Natl Acad Sci U S A 1985 1.36
7 Distinctive properties of the hepatitis B virus envelope proteins. J Virol 1988 1.32
8 Recombinant adenovirus induces antibody response to hepatitis B virus surface antigen in hamsters. Proc Natl Acad Sci U S A 1987 1.31
9 Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci U S A 1989 1.27
10 Protein kinase and its regulatory effect on reverse transcriptase activity of Rous sarcoma virus. Proc Natl Acad Sci U S A 1975 1.13
11 Purification and properties of a beta-lactamase from Proteus penneri. J Antibiot (Tokyo) 1986 1.10
12 Independent assembly of Qbeta and MS2 phages in doubly infected Escherichia coli. Virology 1970 1.05
13 Evaluation of adenovirus type 4 and type 7 recombinant hepatitis B vaccines in dogs. Vaccine 1991 1.03
14 Ribonucleases of Rous sarcoma virus. Virology 1973 1.03
15 Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant. J Virol 1992 1.03
16 Hybridisation of Dane particle DNA with the free plasma DNA of hepatitis carriers. Nature 1975 1.00
17 Colchicine disposition in human leukocytes after single and multiple oral administration. Clin Pharmacol Ther 1993 0.99
18 Expression in Escherichia coli of biologically active enzyme by a DNA sequence coding for the human plasminogen activator urokinase. Proc Natl Acad Sci U S A 1981 0.98
19 Characterization and comparison of the major glycoprotein from three strains of Rous sarcoma virus. Arch Biochem Biophys 1976 0.98
20 Isolation of nucleic acid-binding protein: stimulation of reverse transcriptase-catalysed DNA synthesis. Nature 1976 0.96
21 A new hamster model for adenoviral vaccination. Arch Virol 1988 0.95
22 Discrepancy between the antibacterial activities and the inhibitory effects on Micrococcus luteus DNA gyrase of 13 quinolones. Chemotherapy 1986 0.95
23 Specificity in self-assembly of bacteriophages Q beta and MS2. Biochemistry 1969 0.93
24 Ultrastructural characterization of human immunodeficiency virus type 1 Gag-containing particles assembled in a recombinant adenovirus vector system. J Gen Virol 1991 0.93
25 Identification of residues important for ligand binding to the human 5-hydroxytryptamine1A serotonin receptor. Mol Pharmacol 1993 0.90
26 Sequence of the serotype-specific glycoprotein of the human rotavirus Wa strain and comparison with other human rotavirus serotypes. Virus Res 1985 0.90
27 Alteration in function of transfer ribonucleic acid of Escherichia coli after infection with phage Q beta. J Biol Chem 1968 0.88
28 Effects of purine nucleoside analogues with a cyclobutane ring and erythromycin A oxime derivatives on duck hepatitis B virus replication in vivo and in cell culture and HIV-1 in cell culture. J Med Virol 1991 0.88
29 Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH2-terminal domains on its biochemical and biological properties. J Biol Chem 1988 0.87
30 Efficacy of adenovirus-vectored respiratory syncytial virus vaccines in a new ferret model. Vaccine 1994 0.86
31 Current use and future directions of adenovirus vaccine. Semin Respir Infect 1989 0.85
32 Deglycosylation increases the fibrinolytic activity of a deletion mutant of tissue-type plasminogen activator. Thromb Haemost 1990 0.84
33 Therapeutic efficacy of cefpiramide-ciprofloxacin combination in experimental Pseudomonas infections in neutropenic mice. J Antimicrob Chemother 1987 0.84
34 Substrate specificity of the NS3 serine proteinase of hepatitis C virus as determined by mutagenesis at the NS3/NS4A junction. Virology 1994 0.83
35 Carbohydrate groups in the major glycoprotein of Rous sarcoma virus. Nature 1974 0.82
36 Co-expression of hepatitis B virus antigens by a non-defective adenovirus vaccine vector. Arch Virol 1991 0.82
37 Expression and secretion of human atrial natriuretic alpha-factor in Bacillus subtilis using the subtilisin signal peptide. Gene 1988 0.82
38 Synthesis and refolding of human tissue-type plasminogen activator in Bacillus subtilis. Gene 1989 0.82
39 Selective incorporation of host cell methionyl-transfer RNA by RNA tumor viruses. Biochim Biophys Acta 1974 0.81
40 The reconstitution of infective bacteriophage Q beta. Biochemistry 1969 0.81
41 Elimination of antibiotic-resistant plasmids by quinolone antibiotics. Chemotherapy 1988 0.81
42 Immunogenicity of high expression adenovirus-hepatitis B virus recombinant vaccines in dogs. J Gen Virol 1994 0.81
43 Self-assembly of Q-beta and MS2 phage particles: possible function of initiation complexes. Science 1969 0.81
44 The simian immunodeficiency virus (SIV) rev gene regulates env expression. J Med Primatol 1990 0.80
45 Cell-free protein synthesis dependent on transfer RNA. Biochem Biophys Res Commun 1966 0.80
46 Helper independent recombinant adenovirus vectors: expression of HIV env or HBV surface antigen. Int Rev Immunol 1990 0.80
47 Immunogenicity of recombinant influenza virus haemagglutinin carrying peptides from the envelope protein of human immunodeficiency virus type 1. Vaccine 1994 0.80
48 Interaction of clavulanic acid, sulbactam and cephamycin antibiotics with beta-lactamases. Drugs Exp Clin Res 1987 0.80
49 Coexpression of biologically active simian immunodeficiency virus (SIV) Rev and Env in an SV40 system: the SIV rev gene regulates env expression. Virology 1990 0.80
50 Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus. Vaccine 1995 0.79
51 Comparative antigenicities of Q beta phage, its structural components and reconstituted particles. Virology 1969 0.79
52 Alterations in the domain structure of tissue-type plasminogen activator change the nature of asparagine glycosylation. Biotechnology (N Y) 1990 0.79
53 Chromatographic analyses of isoaccepting tRNAs from avian tumor viruses. J Virol 1974 0.78
54 Construction and characterization of adenovirus co-expressing hepatitis B virus surface antigen and interleukin-6. Gene 1994 0.77
55 Use of DEAE-cellulose for isolation of ribonucleic acids from bacteriophages Q beta and MS. Biochim Biophys Acta 1969 0.77
56 Disposition of a novel recombinant tissue plasminogen activator, delta 2-89 TPA, in mice. Thromb Res 1988 0.77
57 Heparin potentiates endothelial cell growth factor stimulation of plasminogen activator synthesis by diploid human lung fibroblasts. Thromb Haemost 1988 0.77
58 Tissue plasminogen activator (tPA) as a reporter gene in transient gene expression. Gene 1987 0.76
59 Synergistic activity of apalcillin and gentamicin in a combination therapy in experimental Pseudomonas bacteraemia of neutropenic mice. J Antimicrob Chemother 1986 0.76
60 Characterization of the simian adenovirus type 30 inverted terminal repeat. Gene 1989 0.75
61 Experimental efficacy of apalcillin and cefpiramide compared with that of six other antipseudomonal agents in Pseudomonas aeruginosa burn infections. Drugs Exp Clin Res 1986 0.75
62 Clearance of a novel recombinant tissue plasminogen activator in rabbits. Thromb Res 1988 0.75
63 Extensive reverse transcription of RSV genome by nucleic acid-binding protein. Nature 1977 0.75
64 Growth of transformed C-127 cell in bioreactors for large-scale T-PA production. Biotechnology (N Y) 1991 0.75
65 Induction of sustained patency after clot-selective coronary thrombolysis with Hybrid-B, a genetically engineered plasminogen activator with a prolonged biological half-life. Circulation 1991 0.75
66 Relevance of the guinea-pig necrotic inflammation footpad reaction to safety concerns with MDP-based adjuvants. Vaccine 1994 0.75
67 Experimental efficacy and pharmacokinetic properties of cefpiramide, a new cephalosporin. Drugs Exp Clin Res 1985 0.75
68 Site-specific DNA splicing: a general procedure for the creation of a restriction site at a predetermined position in a DNA sequence. Gene 1986 0.75
69 Therapeutic efficacy and pharmacokinetic properties of ciprofloxacin in intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Drugs Exp Clin Res 1987 0.75
70 Correlation between gastric protein kinase and secretion in the pylorus ligated rat. Biochem Pharmacol 1977 0.75
71 Construction and expression of a hybrid plasminogen activator gene with sequences from non-protease region of tissue-type plasminogen activator (t-PA) and protease region of urokinase (u-PA). Gene 1988 0.75
72 Antibody response to bacteriophage Q , and its structural components in rabbits. Immunochemistry 1972 0.75
73 Rescue of chemically inactivated Rous sarcoma virus transforming activity by avian leukosis virus. Virology 1973 0.75
74 Isolation of a human cDNA of urokinase and its expression in COS-1 cells. Gene 1988 0.75
75 Oxime derivatives of erythromycin: inhibitors of Rous sarcoma virus reverse transcriptase activity and focus formation. J Gen Virol 1975 0.75
76 The cloning, isolation and characterization of a biologically active human enzyme, urokinase, in E. coli. Adv Exp Med Biol 1984 0.75
77 Conservation of essential sequences in the major late promoter and tripartite leader of the simian adenovirus type 30. Gene 1990 0.75
78 Therapeutic efficacy of cefpiramide and cefoperazone alone and in combination with gentamicin against pseudomonal infections in neutropenic mice. Chemotherapy 1986 0.75
79 Isolation and characterization of adenovirus-associated VA RNAs of human adenovirus type 7. Gene 1994 0.75
80 Inhibitory activity of cefpiramide on beta-lactamase. Chemotherapy 1985 0.75
81 Genetic engineering of proteins for enhanced therapeutic potential. Crit Rev Eukaryot Gene Expr 1992 0.75